Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Progyny, Inc. (PGNY) SEC filings page on Stock Titan provides direct access to the company’s official U.S. Securities and Exchange Commission documents, along with AI-powered summaries to help interpret the information. Progyny’s common stock is registered under Section 12(b) of the Exchange Act and trades on the Nasdaq Global Select Market, so its filings include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, among others.
For a benefits management company in the healthcare plans sector, annual reports (Form 10-K) and quarterly reports (Form 10-Q) are key sources for understanding revenue from fertility benefit services and pharmacy benefit services, client and member metrics, risk factors, and management’s discussion of operations. AI summaries can highlight how Progyny describes its women’s health and family building solutions, its clinical networks, and the factors that influence utilization and margins.
Current reports on Form 8-K document material events such as quarterly earnings releases, the entry into a revolving credit facility, and executive leadership changes. For example, recent 8-K filings reference financial results for specific quarters, the establishment of a $200 million revolving credit facility under a Credit Agreement, and the planned cessation of employment of the company’s president along with a consulting arrangement. AI analysis can surface the sections that describe these events, summarize their implications, and point to related exhibits.
Investors and analysts interested in executive arrangements, capital structure, and financing can use this page to review disclosures about the revolving credit facility, guarantees by subsidiaries, and covenants such as leverage and interest coverage ratios, as described in the July 1, 2025 Form 8-K. Over time, filings also provide context on stock repurchase authorizations, share-based compensation, and other capital priorities.
The filings page also makes it easier to monitor risk disclosures and regulatory language. Progyny’s safe harbor statements and risk factor summaries discuss competition, client retention, utilization variability, regulatory changes, data security, relationships with providers and pharmacy partners, and other issues that can affect results. With real-time updates from EDGAR and AI-generated explanations, users can quickly locate the most relevant sections of long documents, whether they are reviewing a 10-K, a 10-Q, or a Form 4 related to insider transactions.
Progyny, Inc. furnished an update to its previously issued financial guidance for the three months and full year ending December 31, 2025. The company did this by issuing a press release dated January 12, 2026, which is attached as Exhibit 99.1 to this Form 8-K and incorporated by reference into the disclosure under Item 2.02. The information in this item and the exhibit is being furnished rather than filed under securities laws, meaning it is not subject to certain liability provisions and is not automatically incorporated into other regulatory documents.
Progyny, Inc. announced that the employment of its President, Michael Sturmer, will end effective December 31, 2025, with severance provided under his existing 2021 employment agreement. The company is not appointing a new President, noting that it has strengthened its executive team with recent hires in commercial, technology, operations and product leadership roles.
To support continuity on key projects and strategic initiatives, Sturmer will remain as a non-employee consultant through December 31, 2026, under a new consulting agreement. He will receive an annual advisory fee of $250,000, and if he continues to serve through June 30, 2026, his outstanding and vested stock options will have their exercisability extended proportionally to the period of consulting services. The full consulting agreement will be filed as an exhibit to Progyny’s Annual Report on Form 10-K for the year ending December 31, 2025.
Progyny, Inc. reported an insider stock transaction by its chief financial officer, Mark S. Livingston. On December 11, 2025, he sold 459 shares of Progyny common stock at $25.5 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that was entered into on August 15, 2025. Following this transaction, he directly owns 46,983 shares of Progyny common stock.
Progyny, Inc.'s president reported a routine equity compensation-related share withholding. On 12/04/2025, 7,977 shares of common stock were withheld at $24.55 per share to pay withholding taxes triggered by the vesting of restricted stock units granted to the officer. After this transaction, the president directly beneficially owned 288,233 Progyny shares.
Progyny, Inc. (PGNY) reported an insider stock sale by its Chief Financial Officer. On 11/17/2025, the CFO sold 21,303 shares of Progyny common stock at a price of $25.50 per share, as shown in Table I of the filing. After this transaction, the CFO beneficially owns 48,358 shares of common stock in a direct capacity.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that was entered into on August 15, 2025. These plans allow insiders to systematically sell shares according to preset instructions, helping separate personal liquidity decisions from day-to-day company developments.
Progyny, Inc. (PGNY) director reported an option exercise and a share transfer. On 11/14/2025, the reporting person exercised a stock option for 36,224 shares of common stock at $1.45 per share, paying the exercise price in cash and holding all shares received, with no shares sold in connection with the exercise.
On 11/18/2025, the reporting person transferred 50,265 shares held directly to The Norman C. and Melinda B. Payson Revocable Trust for no consideration, reported as a gift. Following these transactions, the person held common stock directly and also indirectly through the revocable trust and through EVO Eagle, LLC, over which the reporting person shares voting and dispositive power.
Progyny, Inc. (PGNY) disclosed that its Chief Executive Officer and director purchased 79,500 shares of common stock on 11/13/2025. The shares were bought at a weighted average price of $24.288 per share, in multiple trades at prices ranging from $23.73 to $24.52. Following this transaction, the reporting person beneficially owns 680,251 shares directly and an additional share indirectly through PECO ANEVSKI 2020 SD LLC. The filing notes that the purchase was made to offset a tax withholding obligation arising from the net settlement of performance stock units reported the same day.
Progyny, Inc. (PGNY) Form 4: The Executive Chairman and director reported the vesting and settlement of performance stock units. On 11/10/2025, 41,500 PSUs granted on January 1, 2022 were settled into common stock after the Compensation Committee certified performance on 10/31/2025.
To cover withholding taxes upon vesting, 21,286 shares were withheld at $22.37. Following these transactions, the reporting person directly beneficially owns 240,633 shares. These entries reflect equity award settlement and related tax withholding, not an open‑market purchase or sale.
Progyny, Inc. (PGNY)
On November 10, 2025, the reporting person acquired 125,000 shares of common stock at $0 upon settlement of PSUs that vested on October 31, 2025, after certification of performance. On the same date, 63,813 shares were withheld to cover taxes at a price of $22.37 per share. Following these transactions, the filer beneficially owned 600,751 shares directly, plus 1 share held indirectly.
Progyny, Inc. (PGNY) reported stronger Q3 2025 results. Revenue rose to $313.3M from $286.6M, with gross profit of $72.8M. Operating income increased to $21.5M and net income reached $13.9M, or $0.15 diluted EPS. For the first nine months, revenue was $970.3M and net income was $46.0M, reflecting solid year-to-date performance.
Liquidity remained healthy: cash and cash equivalents were $134.0M and marketable securities were $211.2M at quarter end. Operating cash flow for the nine months was $156.0M. The company entered a $200M revolving credit facility maturing in 2030, with no borrowings outstanding, and later authorized a new $200M share repurchase program in November 2025. Total assets were $795.2M and stockholders’ equity was $560.0M. As of October 31, 2025, 86,211,654 common shares were outstanding.
Client base and utilization supported growth: Q3 fertility benefits revenue was $201.9M and pharmacy benefits revenue was $111.4M. The company closed the Benefit Bump acquisition for $10.5M to extend family support offerings.